CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday

Key Points

• CeriBell (CBLL) is set to announce its Q2 2025 earnings on August 5th, with expected earnings of ($0.40) per share and revenue of $20.52 million.
• Insider selling has occurred recently, with Director Rebecca B. Robertson and CEO Xingjuan Chao reducing their stakes, indicating potential concerns about stock performance.
• Currently, CeriBell holds a consensus "Buy" rating from analysts, with a target price around $32.14.

CeriBell (NASDAQ:CBLL - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect CeriBell to post earnings of ($0.40) per share and revenue of $20.52 million for the quarter. CeriBell has set its FY 2025 guidance at EPS.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to the consensus estimate of $19.30 million. On average, analysts expect CeriBell to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CeriBell Trading Down 1.8%

Shares of NASDAQ:CBLL traded down $0.26 during trading on Friday, reaching $14.14. 270,452 shares of the company's stock traded hands, compared to its average volume of 206,681. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.36 and a quick ratio of 16.81. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75. The company has a 50 day moving average of $17.02 and a 200-day moving average of $18.79.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CBLL shares. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. BTIG Research initiated coverage on shares of CeriBell in a research note on Tuesday, June 24th. They set a "buy" rating and a $30.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.14.

Insider Buying and Selling

In other news, Director Rebecca B. Robertson sold 11,188 shares of the company's stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $17.85, for a total value of $199,705.80. Following the completion of the sale, the director directly owned 10,042 shares of the company's stock, valued at approximately $179,249.70. This represents a 52.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $17.70, for a total transaction of $442,500.00. Following the completion of the sale, the chief executive officer directly owned 776,022 shares of the company's stock, valued at approximately $13,735,589.40. This represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,633 shares of company stock valued at $1,965,261. Company insiders own 20.10% of the company's stock.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.